Zobrazeno 61 - 70
of 1 389
pro vyhledávání: ''
Publikováno v:
Cancer Research. 76:P3-07
Background: Breast malignancies continuously shed tumor cells which may enter the circulation, spread to other tissue and initiate metastases, but only a small subpopulation among CETCs is capable of metastasis formation. The subpopulation of CETC ca
Autor:
QT Bui, Keon Wook Kang
Publikováno v:
Cancer Research. 76:P1-05
Epithelial-mesenchymal transition (EMT) is process in which epithelial cells undergo unique morphologic changes characterized by a transition from epithelial cobblestone phenotype to elongated fibroblastic phenotype (mesenchymal phenotype) leading to
Publikováno v:
Cancer Research. 76:P3-14
Background: Triple negative breast cancers (TNBC) that lack estrogen receptor (ER), progesterone receptor (PR) and hormone epidermal growth factor receptor 2 (HER-2/neu) are aggressive and cause high mortality among breast cancer patients. Transformi
Autor:
Xiaoping Gu, Xiaowei Chen, Maria I. Zavodszky, Chinnappa D. Kodira, Yesim Gökmen-Polar, Sunil Badve
Publikováno v:
Cancer Research. 76:P2-06
Background: LncRNAs may play a role in cancer and serve as new potential targets for improving cancer diagnosis, prognosis or treatment. Long intergenic non-protein coding RNA 478 (LINC00478), the miR99a-let-7c cluster host gene, has been shown to be
Publikováno v:
Cancer Research. 76:P2-08
Introduction: Tumor related inflammation plays an important role in breast cancer progression, tumor-associated macrophages (TAMs) being a crucial part of this microenvironment. Platelet-derived growth factor-C (PDGF-C) is abundant in the breast canc
Publikováno v:
Cancer Research. 76:P2-05
Breast cancer most commonly metastasizes to bone where metastases cause the potentiation of the vicious cycle. During this process, breast cancer bone metastases inhibit osteoblasts from forming new bone, while also activating osteoclasts to degrade
Autor:
Meritxell Bellet, V Ortega, P. Nuciforo, Lorena Fariñas, Cristina Cruz, Ludmila Prudkin, Jose Perez-Garcia, Marcos Vinicius Silva Oliveira, José Antonio Jiménez, Maria Vidal, A Meire, J. Cortes, Esther Zamora, E Muñoz Cosuelo, Claudia Aura, F Salva, Patricia Gomez, M Diaz-Delgado, J Soberino, Cristina Saura
Publikováno v:
Cancer Research. 76:P4-09
BACKGROUND: In recent years, changes in HER2 and hormone receptor (HR) status between primary and metastatic breast cancer (BC) have been extensively reported. Additionally, current advances in BC biology have identified emerging biomarkers with clin
Autor:
Jiri Navratil, L Bareková, Markéta Palácová, Jaroslav Juracek, Pavel Fabian, I Selingerová, Marek Svoboda, V Fait, T Kabut, O Coufal
Publikováno v:
Cancer Research. 76:P1-07
Background: TNBC represents a heterogeneous group of breast cancers that do not express ER-α, PgR and Her-2 receptors. Generally, these tumors are aggressive and more common in younger women. The aim of our study was to create a representative set o
Publikováno v:
Cancer Research. 76:P1-16
Clinical trials and epidemiological evidence show that combined estrogen (E) and progestin (P) hormone replacement therapy (HRT) increases the risk of breast cancer in postmenopausal women, whereas HRT containing E alone does not. Tumor progression i
Autor:
Alexander R. A. Anderson, Gustavo Ayala, Ziv Frankenstein, Simon W. Hayward, David Basanta, Omar E. Franco
Publikováno v:
Cancer Research. 75:B2-53
Prostate cancer (PCa) is ranks fourth in worldwide cancer incidence. Gleason (epithelial cancer marker) is the standard metric for defining prostate cancer aggressiveness. Still, PCa is difficult to predict using available prognostic data. Stromal-tu